Corporate Overview
At SurroMed, we are creating a therapeutic discovery and development company whose mission is to enable the precise diagnosis and personalized treatment of disease. We are establishing a unique capability for human disease research and biological marker-enabled drug development that leverages our proprietary, integrated technology platform for molecular phenotyping and biological marker discovery. Our approach will enable significant improvements in the expensive and risky clinical drug development process, which typically generates only one marketed therapeutic product for every five candidates that enter human testing. We are conducting phenotyping and biological marker discovery research programs in a number of disease and therapeutic areas, including: rheumatoid arthritis, osteoarthritis, allergy and asthma, cardiovascular disease, diabetes and Alzheimer's disease. These clinical research studies will (1) discover biological markers useful for a variety of applications, including stratifying patients by disease type and response to therapy, and (2) identify and validate therapeutic and diagnostic targets.
Molecular Phenotyping and Biological Marker Discovery: Applications
An organism's phenotype is its overall biochemical and physiological state at a given point in time and can be characterized by biological markers. Biological markers are objectively measurable phenotypic parameters that characterize an organism's state of health or disease, or response to a particular therapeutic intervention. The complex interaction of the genotype with a multitude of environmental influences -- infectious agents, lifestyle, diet, stress, chemical exposure and other factors -- results in a molecular phenotype, which is expressed in the form of soluble and cell-surface proteins and low molecular weight biomolecules (for example, sugars, fatty acids and steroids.) Because this physical manifestation of genes and environmental factors is where biology actually happens, molecular phenotyping is critical to understanding disease processes, drug actions and how they differ among patients with outwardly similar clinical signs and symptoms.
SurroMed is addressing the need for new strategies and technologies for molecular phenotyping and biological marker discovery to improve understanding of disease and the pharmaceutical industry's ability to develop new therapeutic products efficiently and cost effectively. SurroMed employs a highly integrative approach to molecular phenotyping and biological marker discovery in humans that combines (1) capture of patient clinical signs and symptoms obtained by physical examination with (2) broad bioanalytical profiling and measurement of blood, urine and other biological samples with proprietary technologies. Important outputs of SurroMed's research process are biological markers that have a wide range of pharmaceutical and diagnostic applications spanning the discovery, development and commercialization continuum, including:
At SurroMed, we are creating a therapeutic discovery and development company whose mission is to enable the precise diagnosis and personalized treatment of disease. We are establishing a unique capability for human disease research and biological marker-enabled drug development that leverages our proprietary, integrated technology platform for molecular phenotyping and biological marker discovery. Our approach will enable significant improvements in the expensive and risky clinical drug development process, which typically generates only one marketed therapeutic product for every five candidates that enter human testing. We are conducting phenotyping and biological marker discovery research programs in a number of disease and therapeutic areas, including: rheumatoid arthritis, osteoarthritis, allergy and asthma, cardiovascular disease, diabetes and Alzheimer's disease. These clinical research studies will (1) discover biological markers useful for a variety of applications, including stratifying patients by disease type and response to therapy, and (2) identify and validate therapeutic and diagnostic targets.
Molecular Phenotyping and Biological Marker Discovery: Applications
An organism's phenotype is its overall biochemical and physiological state at a given point in time and can be characterized by biological markers. Biological markers are objectively measurable phenotypic parameters that characterize an organism's state of health or disease, or response to a particular therapeutic intervention. The complex interaction of the genotype with a multitude of environmental influences -- infectious agents, lifestyle, diet, stress, chemical exposure and other factors -- results in a molecular phenotype, which is expressed in the form of soluble and cell-surface proteins and low molecular weight biomolecules (for example, sugars, fatty acids and steroids.) Because this physical manifestation of genes and environmental factors is where biology actually happens, molecular phenotyping is critical to understanding disease processes, drug actions and how they differ among patients with outwardly similar clinical signs and symptoms.
SurroMed is addressing the need for new strategies and technologies for molecular phenotyping and biological marker discovery to improve understanding of disease and the pharmaceutical industry's ability to develop new therapeutic products efficiently and cost effectively. SurroMed employs a highly integrative approach to molecular phenotyping and biological marker discovery in humans that combines (1) capture of patient clinical signs and symptoms obtained by physical examination with (2) broad bioanalytical profiling and measurement of blood, urine and other biological samples with proprietary technologies. Important outputs of SurroMed's research process are biological markers that have a wide range of pharmaceutical and diagnostic applications spanning the discovery, development and commercialization continuum, including:
- Ø Improved clinical drug development strategies that are less costly and executed more rapidly because they require fewer patients, shift go/no-go decisions to earlier stages of the development process, and reduce costly late-stage failures.
Ø Value-enhancement for existing therapeutic products via rapid/early identification of responders and non-responders, improved differentiation, optimized dosing regimens tailored to the needs of individual patients, and identification of new mechanisms and indications.
Ø Rescue of "stalled" pharmaceutical product candidates that have demonstrated equivocal efficacy in clinical trials.
Ø Screening, diagnostic, prognostic and therapeutic monitoring test services and products that enable early disease detection, patient stratification, therapy selection and rapid evaluation of therapeutic response.
Ø Insight into disease processes in individuals who do not respond to current therapeutics, thereby enabling discovery and development of new therapeutics for these under-served patients.
Ø Improved in vivo and in vitro models with greater predictive power.
Ø Identification, validation and prioritization of novel drug targets.
Ø Information products and algorithms that facilitate improved clinical decision-making and patient outcomes, as well as cost-effective healthcare delivery.